IP Starts Recovering, but the Earnings Raise Still Runs Ahead of the Growth Raise

Results vs. Consensus

Q2 FY26 scorecard

Delivery against company guidance

Year-over-year comparison

Quarter-over-quarter comparison

Revenue: The 41.9% headline increase principally reflects acquired Ansys revenue. EDA grew 8.3%, while IP remained below last year. The sequential group decline was anticipated: Ansys’s former December year-end now falls in Synopsys’s first quarter. EDA and IP both grew sequentially in Q2, so the consolidated decline does not overturn Q1’s recovery thesis; it does show why the combined company needs analysis by product group.

Margins: The non-GAAP operating margin of 39.5% exceeded the roughly 38.0% implied by the previous revenue and expense midpoints. Channel accounting modestly diluted the reported margin because it added no profit. The economic gain comes from removing duplicate costs and better IP utilization, although the 42.1% Q1 margin was aided by a stronger revenue mix and should not be extrapolated across the year.

EPS: The beat is operational, with an 18% non-GAAP tax rate matching the guide. Net interest and other expense was about $115.0M, essentially the prior midpoint. Year over year, non-GAAP net income rose 12.4%, but a 23.1% larger diluted share base pulled EPS down 8.7%. The acquisition has expanded profit faster than it has repaired per-share economics.

GAAP earnings tell a less flattering near-term story: $403.6M of acquired-intangible amortization, $222.3M of stock compensation and $115.9M of restructuring were excluded from non-GAAP results. Amortization is largely a purchase-accounting effect, but compensation dilutes owners and restructuring consumes resources. We value the recurring business on non-GAAP EPS while retaining a valuation discount for the cash, dilution and execution costs that the adjusted measure does not capture.

Segment Performance

Product groups: EDA and IP improve as Ansys seasonality reverses

Ansys is part of Design Automation; the product-group table is an alternative breakdown of the same revenue. Amounts may not sum exactly because of rounding.

Design Automation: hardware wins support growth, with a narrower demand base

Hardware-assisted verification remained the main EDA growth driver, with emulation and prototyping wins across ZS5, ZeBu and HAPS-200. More than 30 full-flow technical wins and a production AI-accelerator tapeout using the 3DIC Compiler platform support the advanced-node franchise. These engagements span both merchant chip suppliers and hyperscalers building their own silicon, allowing Synopsys to participate as design activity shifts between customer groups.

“We are maintaining our EDA leadership position, supported by the success of recent renewals, pipeline activity and monetization trends.”
— Sassine Ghazi, President and CEO

Assessment: EDA’s 8.3% growth provides an operating foundation for our FY27 outlook, but it is below the long-term double-digit ambition. Hardware timing can move growth between quarters, and muted non-AI design starts limit breadth. We expect further expansion from advanced-node complexity; we do not assume a broad industrial design recovery to reach our base estimate.

Ansys: integration is working; the new products are still in trials

Ansys contributed $639.9M excluding the channel gross-up. The decline from Q1’s $885.6M is consistent with the seasonal pattern management described in February. Annual Ansys guidance remains $2.9B before the $60M accounting addition, so the quarter does not establish a higher full-year underlying revenue trajectory. Simulation demand extends beyond semiconductors into data-center infrastructure, aerospace and defense, and automotive system development.

“In Q2, we saw continued demand for system-level digital engineering and physics-based simulation across industries.”
— Sassine Ghazi, President and CEO

Assessment: Q1’s concern that calendar integration could disrupt the acquired sales engine has diminished. The original portfolio is contributing while cross-selling and joint products develop. That is sufficient to support our revenue forecast, but the unchanged underlying Ansys guide keeps us from capitalizing a new synergy growth rate today.

Design IP: the first promised sequential recovery is visible

IP revenue increased $47.2M sequentially, and adjusted operating income rose from $66.1M to $110.6M. The 820bp margin recovery to 24.4% shows that additional revenue can absorb the engineering investment behind new titles. It also leaves margin 680bp below last year’s 31.2%, so a single recovery quarter has not restored the segment’s economics.

“While we continue to expect muted IP growth for fiscal year 2026, we believe the IP segment bottomed in Q1 and has begun its recovery. We expect sequential quarterly improvement throughout the second half, supported by our road map, execution and pipeline.”
— Sassine Ghazi, President and CEO

Assessment: This meets the first signpost in our Q1 Hold case. The recovery is based on the existing pipeline and business model, not prospective royalties. We now give greater weight to an orderly transition, while retaining the risk that title delivery or customer schedules delay the remaining back-half improvement.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management was more explicit than in Q1 about the IP trough and more confident about cost delivery. It remained exploratory on new pricing models and deferred the remaining synergy timetable to Investor Day, so conviction was strongest around execution of the current plan.

1. Cost savings are becoming earnings, while restructuring stays economically relevant

The FY26 non-GAAP operating-margin target rises to 41%, from 40.5%. Management expects to be approximately halfway through the $400M cost-synergy commitment by fiscal year-end, a roughly $200M run-rate milestone. This is a pace-of-exit target, not $200M of incremental FY26 profit to add to guidance.

“We expect to be approximately halfway through our committed cost synergy realization by the end of fiscal year 2026.”
— Shelagh Glaser, CFO

The new non-GAAP expense midpoint falls $20M to $5.700B even after the $60M channel-expense addition. On that common basis, the plan absorbs $80M less expense, although the divestiture and business mix also affect the comparison. Combined with the $55M reported revenue increase, that raises implied operating profit by $75M. It is enough to support the earnings revision without assuming a near-term pricing windfall.

Assessment: The cost side of the Ansys thesis is now more credible than the revenue-synergy side. Our FY27 margin assumption increases to 42.5%, still below the long-term mid-40s objective, because savings must coexist with investment in new IP and software.

2. Multiphysics Fusion advances the product promise, with commercial delivery still ahead

Converge has moved the Q1 joint-solutions discussion from an unnamed first wave to a specific technology and customer trials. Early results include up to three-times faster design closure and up to two-times faster turnaround for complex analog designs. These are customer-trial outcomes, not revenue growth rates or guaranteed results across all designs.

“Multiphysics Fusion is currently in expanding trials with leading customers and will begin ramping into commercial availability in the second half of 2026.”
— Sassine Ghazi, President and CEO

The commercial opportunity is to bring thermal, structural and other physics analysis earlier into chip design, reducing the expensive iterations that occur when problems are found near signoff. Management says access to the integrated capability must carry additional value beyond customers’ existing Synopsys and Ansys licenses. Monetization remains a FY27 event.

Assessment: The narrower promise of initial partner access has progressed, but broad commercial availability has not yet arrived. Our Q1 condition of credible product visibility is partly met; it does not justify treating the full $400M year-four revenue-synergy target as FY27 sales.

3. AI and GPU acceleration offer a pricing mechanism, not yet a new growth rate

Management cited early contract uplift for GPU-accelerated EDA and 20 customers evaluating more than 25 specialized agents. The distinction matters: faster underlying solvers can support a premium today, while agent consumption introduces a different revenue mechanism whose pricing is still being negotiated.

“The current thinking, and we're in early exploration with customers, is how do we build from the subscription license that our customer has for the human engineers to run our product to subscription plus consumption for the agents to utilize our products.”
— Sassine Ghazi, President and CEO

Assessment: The Q1 NVIDIA and agentic-AI watch items have gained commercial substance, but adoption and monetization need separate forecasts. We expect higher tool usage as agents execute more design work; the base case contains ordinary EDA growth and modest margin improvement, without a separate consumption-revenue surge.

4. Custom silicon strengthens IP bargaining power before royalties begin

Hyperscalers need foundry-qualified interface and memory IP to make custom chips competitive with merchant alternatives. Synopsys can therefore seek a larger share of the value of its IP beyond a traditional use fee or engineering payment. The greater-than-90% PCIe 7.0 win rate and more than 150 lifetime UCIe wins support the relevance of that portfolio; they do not establish equivalent market share across all IP.

“We're making actually very good progress, as I mentioned a number of quarters ago, by the end of this fiscal year, we will have few customers with signed agreements with a new business model that provides the opportunity to capture more dollar than the traditional use fee or some level of NRE.”
— Sassine Ghazi, President and CEO

Assessment: This creates a dated contract milestone for the prior IP-recovery thesis. The first sequential improvement arrived under the existing model, so royalties remain potential upside. Greater customization can also require more engineering work; signed agreements need to show profitable value capture, not simply a larger contract face value.

5. Elliott adds board-level accountability to an existing operating agenda

The cooperation agreement appoints Jesse Cohn as an independent director effective June 1. His initial term runs to the 2027 annual meeting, and the agreement includes voting and standstill provisions. Management described alignment on monetization and operating efficiency, with September 30 Investor Day becoming the next opportunity to translate that alignment into targets.

“On the operating margin, there's no debate. There's an efficiency as well that we can drive.”
— Sassine Ghazi, President and CEO

Assessment: Board involvement increases accountability for the margin and pricing agenda; it is not itself an earnings catalyst. We assign no separate activist premium because the reported savings already enter our estimates, while the new business models still need customer agreement.

6. Buybacks begin, but cash generation must also support the balance sheet

Synopsys committed $300M to repurchases in Q2: a $250M accelerated program and $50M in the open market. The accelerated program’s final settlement is expected by June 1. This is progress against Q1’s authorization, but remains below the $500M–$1B FY26 execution range we previously expected.

“We are raising our cash flow from operations guidance to approximately $2.3 billion. Our CapEx guidance of approximately $300 million remains unchanged, resulting in free cash flow of approximately $2 billion, an increase of $100 million versus our previous guidance.”
— Shelagh Glaser, CFO

H1 free cash flow reached $1.396B, leaving about $604M required in H2 to meet the new annual target. The apparent cushion partly reflects $89.5M of H1 capex versus the $300M annual plan, and cash collections are seasonal. With approximately $7.55B of net debt, excess cash still has a valuable alternative use in reducing financing risk.

Assessment: Capital allocation has moved from authorization to execution, satisfying part of the Q1 checklist. We retain a $500M FY26 buyback assumption and keep FY27 diluted shares at 193M; we do not assume repurchases fully offset stock compensation or eliminate the remaining debt burden.

7. China and non-AI design activity limit the breadth of the recovery

China revenue was $240.4M, up from $211.1M sequentially and $157.5M a year earlier. Ansys consolidation and an easy comparison affect that growth, and management left its China forecast unchanged. The company also distinguished improving industrial and automotive customer sales from still-muted analog design starts.

“And even with China, there isn't much in terms of change from what we've communicated before, where the design start environment in China remains challenged given all the restrictions and the cumulative impact of the restrictions.”
— Sassine Ghazi, President and CEO

Assessment: Reported regional growth does not resolve the China risk that constrained our Q1 rating. AI-led design demand can offset some weakness, but a wider geographic or end-market recovery is not yet part of the evidence supporting higher estimates.

8. The processor-IP sale focuses resources and changes the comparison

The pending Processor IP Solutions sale, announced in Q1, is expected to close shortly and removes about $40M of remaining FY26 revenue from guidance. This sharpens the emphasis on interface and foundation IP used in advanced AI systems, while reducing reported revenue available to show a recovery.

“Also advancing our IP strategy, we expect to close the pending sale of the Processor IP Solutions business shortly.”
— Sassine Ghazi, President and CEO

Assessment: The portfolio rationale remains consistent with our Q1 view, but completion is still pending at this cutoff. The next two quarters must demonstrate sequential improvement while absorbing the divestiture, making execution of the remaining title roadmap more important than the headline growth percentage alone.

Guidance & Outlook

Margin and cash-flow guidance are point targets. The revenue bridge is $9,610M + $35M business performance + $60M channel accounting − $40M processor-IP divestiture = $9,665M. Before the accounting and portfolio changes, the improvement is only 0.4% of the prior revenue plan. Ansys’s $2.96B contribution includes the entire $60M channel effect, leaving its underlying $2.9B expectation unchanged.

Implied second-half ramp: H1 revenue of $4,684.8M leaves $4,980.2M to reach the FY26 midpoint. After Q3’s $2,435M midpoint, implied Q4 revenue is $2,545.2M, or 4.5% sequential growth. The annual operating-profit target of about $3,965M, less H1’s $1,913.4M, requires roughly $2,051.6M in H2, a 41.2% margin. This is a further improvement from Q2 but below Q1’s seasonal peak, making the framework achievable without an abrupt change in demand.

Street comparison: The FY26 revenue midpoint is just $35M above the $9.63B consensus, while $14.76 non-GAAP EPS is $0.31 above the $14.45 estimate. The Q3 revenue midpoint is $25M above the $2.41B estimate. That pattern reinforces the argument: profits are improving faster than the underlying sales outlook.

Guidance style: Two quarters above EPS guidance support confidence in execution, but the revenue beat this quarter is small after removing the gross-up. We use the raised annual midpoints as our FY26 estimates. The remaining acceleration depends on IP title availability and hardware delivery timing, with no Intel foundry upside embedded in management’s FY26 plan.

Analyst Q&A Highlights

What makes the IP recovery different from early customer drawdowns?

The question tested whether the sequential improvement was pulled forward or reflected the expected pipeline. Management grounded Q2 in existing contracts and distinguished that recovery from enthusiasm for a new model.

Q: “I wanted to ask about your IP business. It seems like it was through the trough, as you may call it. Did you close any business earlier than expected or see some earlier drawdown? So I'm just trying to understand the sequential improvement commentary. Like are you upticking on IP here?”
— Jason Celino, KeyBanc Capital Markets

A: “the current IP sequential improvement is based on the pipeline that we've had and closing the engagements that we could see in our forecast with the existing business model that we have with our customers. Where you are seeing a strong confidence and enthusiasm is the engagement around the new business model, in particular, in HPC and the AI-based chips with the hyperscalers.”
— Sassine Ghazi, President and CEO

Assessment: The answer supports an operating recovery without relying on royalty assumptions. It does not promise that every subsequent quarter will repeat Q2’s 11.6% increase; additional titles still have to become available for customers to use.

Which business actually earned the revenue increase?

The question sought a segment split for the $35M performance raise. The response explained broad AI demand but did not allocate the incremental dollars.

Q: “I was wondering if you could help us just kind of understand of the $35 million increase to the full year guide on the revenue outlook from business performance, how much of that was related to EDA versus IP?”
— Joseph Quatrochi, Wells Fargo

A: “For us, it's a great opportunity on both ends on the semiconductor suppliers as well as the hyperscalers because for any of these designs, you will need EDA software, you need hardware-assisted verification to verify the chip in the context of the software and IP. For any chip start, you need IP. So the strength was across the portfolio.”
— Sassine Ghazi, President and CEO

Assessment: The mechanism is credible, but the answer does not establish that IP drove the guidance raise. Our forecast uses the small consolidated improvement and the disclosed IP trajectory, without assigning the full $35M to a favored segment.

When does Intel foundry activity become revenue?

The question focused on the expanding 18A and 14A pipeline. Management distinguished evaluations from customers committing to production and explicitly excluded upside from the current annual plan.

Q: “with regards to your largest customer, it sounds like 18A and 14A pipeline is building. Have you seen any of that benefit? And if not, how and when does it start to impact your numbers?”
— Liam Pharr, BofA Securities

A: “Now to remind you, we get paid once the customer commits to the technology and they want to go into production. During the eval phase, it's just an eval. Once it goes into production, we get paid for it. So in terms of how are we taking it into account for FY '26, we're not accounting or taking into account in our guidance any upside. But as these wins move from an eval into production, we'll absolutely see the upside.”
— Sassine Ghazi, President and CEO

Assessment: Foundry diversification offers upside but cannot be booked simply because an evaluation pipeline grows. Our base case carries no discrete Intel conversion windfall; production commitments would create a reason to revisit the IP outlook.

Does recovering analog demand translate into design starts?

The question linked better analog chip sales to potential renewal and design activity. Management separated the customer revenue cycle from the engineering activity that drives demand for its tools.

Q: “I think the evidence is there in the marketplace that a lot of these big analog chip companies are seeing much improved business environment. So therefore, have you seen sort of a resurgence in that customer base from a renewal activity perspective or just in general chip design activity?”
— Gary Mobley, Loop Capital

A: “What we are seeing is a chip start increase or a design start increase in anything AI-related. In industrial and automotive, while customers are reporting strength in revenue, there are multiple reasons for that, but the design starts are not growing -- definitely not growing at the pace as we're seeing for the other cohort.”
— Sassine Ghazi, President and CEO

Assessment: The response argues against adding a broad non-AI cyclical recovery to current estimates. Physical AI may eventually expand design work, but improved shipments at customers are not yet producing comparable design-start growth.

Why can Multiphysics Fusion earn more than existing signoff tools?

The question challenged the incremental opportunity when both companies already hold strong signoff positions. The response located the added value earlier in the design process, where thermal and structural problems can be avoided before final validation.

Q: “I want to go back to Multiphysics Fusion, and is the greatest initial applicability really within signoffs? And I ask because you -- Synopsys and Ansys already had very high market share in signoffs, respectively. But I think the opportunity is probably accelerating at the category level, just given what's happening around advanced packaging. And that certainly brings a lot more signoff challenges into design efforts. And so is it really a case where the overall pie is starting to grow and the bringing together of your 2 companies into this new format is going to capitalize on that?”
— Joseph Vruwink, Baird

A: “The complexity of -- beyond electronics into structure, fluid, thermal, taking these factors into account during the design phase, we have the leadership position in 3DIC Compiler and Fusion Compiler, bringing that technology in during the design phase, so our customers have a convergent flow, so they're not running into surprises later in the flow is the value we're adding to customers as much as the signoff piece is important bringing some of these algorithm and solvers early in the design phase is the value that we are -- will engage the customer on.”
— Sassine Ghazi, President and CEO

Assessment: The explanation supports an incremental product rather than simple bundling of existing licenses. It strengthens the FY27 opportunity, while leaving the amount customers will pay and the pace of adoption as the decisive commercial questions.

Can cost reductions coexist with the hiring required for the roadmap?

The question contrasted lower headcount with rising open positions and asked how investment would coexist with the announced workforce reduction.

Q: “On the other hand, what's interesting is that over the last number of months, there's been an unmistakable sequential uptrend in your open positions for both Synopsys classic and Ansys classic. As an example, Synopsys classic positions are more than 4x the number at the end of Q4, Ansys classic more than double where they were a few months ago. So maybe talk about what you're thinking of with respect to bringing people in as per those numbers versus, on the other hand, reducing your headcount to keep the margins in line?”
— Jay Vleeschhouwer, Griffin Securities

A: “But at the same time, we're also investing in critical areas and making sure that we've got the right technical folks, both in the go-to-market and on the engineering side to deliver the road map that Sassine has been talking about. So we are doing a mix of reducing in areas that are not priorities for us while we are investing in key priorities for ourselves.”
— Shelagh Glaser, CFO

Assessment: The response supports targeted reallocation, not an assumption that every headcount reduction falls straight into profit. Our 42.5% FY27 margin allows continued investment; delayed IP titles or weak commercial support would challenge the quality of the savings even if expenses meet plan.

What They’re NOT Saying

1. The economics of the new IP agreements: Management expects several signed agreements by fiscal year-end, but has not specified rates, volume thresholds or the timing of meaningful revenue. Customization may raise revenue and engineering obligations together.
2. A quantified agentic pricing uplift: Subscription plus consumption remains in exploration. Customer evaluations establish engagement, while incremental paid usage will determine whether AI changes the revenue trajectory.
3. The remaining cost-synergy timetable: The halfway milestone is clearer, but the schedule for the remainder is deferred to Investor Day. That leaves uncertainty around how quickly margins move beyond FY26’s 41%.
4. Underlying China growth and new-bookings momentum: Consolidation affects regional comparisons, and backlog alone does not separate renewals, contract duration and new demand. Neither headline proves that the previous geographic constraint has cleared.
5. Broad rollout milestones and a full FY27 framework: Partner trials and second-half availability are distinct from commercial scale. The stock’s next leg depends on converting the product pipeline into a measurable annual earnings contribution.

Market Reaction

• Pre-print setup: SNPS closed May 27 at $525.92, up 12.0% year to date, 5.5% over the preceding 30 days and 2.8% over twelve months. Its pre-print 52-week closing range was $380.47–$645.35.
• Initial response: Shares declined in after-hours trading despite the earnings and guidance increases.
• May 28 reaction session: Open $510.00, range $471.69–$526.09, close $480.64, down $45.28 or 8.6%.
• Volume and benchmark: Approximately 4.7M shares traded against a 1.6M 30-day average, or 2.9 times normal. The S&P 500 rose 0.6% in the same session.

The relative decline points to a company-specific reassessment, though price action cannot identify a single cause. Our interpretation is that expectations for a more pronounced growth acceleration ran ahead of a quarter whose strongest improvement was cost-driven. The small underlying revenue raise, an IP business still below last year and commercial upside still tied to FY27 provide a coherent explanation for that disappointment.

The selling does not erase the IP margin recovery or the cash-flow increase. It does reduce the premium investors pay while waiting for new products and pricing to contribute. We regard that as a better entry valuation for an improving business, but the remaining downside if execution slips prevents the selloff alone from establishing Outperform.

Street Perspective

Debate 1: Is the IP trough enough to underwrite a growth recovery?

Bull view: Sequential revenue and margin improvement show that the reallocation toward AI and interface IP is beginning to work. New commercial terms with hyperscalers can add another source of growth after the existing title roadmap catches up.

Bear view: IP remains below last year, muted FY26 growth is unchanged, and the pending sale reduces the revenue base. New agreements may take time to produce royalties and may require substantial custom engineering.

Our take: The quarter favors the operational recovery case. We increase confidence in the existing roadmap, but keep new royalty economics outside our base case until contracts establish the value and timing.

Debate 2: Do accelerated savings justify a higher valuation?

Bull view: Earnings and cash-flow guidance rise while cost synergies arrive faster, and board-level involvement can reinforce discipline. Several post-print targets moved higher on that combination.

Bear view: Savings can lift EPS without solving a modest growth rate, while restructuring and stock compensation remain large. Valuing all adjusted earnings as if they had no associated dilution or reinvestment cost would overstate the improvement.

Our take: The savings justify higher earnings estimates, not a separate multiple expansion. Our unchanged fair-value range captures better profit delivery while retaining a discount for incomplete IP recovery and the cost of achieving the new operating structure.

Debate 3: Is the integrated portfolio a revenue catalyst or a longer wait?

Bull view: Combining physics with design addresses problems that separate tools leave until late in the workflow. GPU acceleration and AI agents create more opportunities to charge for engineering productivity.

Bear view: The products are still moving through trials, customers already own many of the underlying tools, and industrial design demand remains uneven. A stronger strategic position need not immediately produce faster recognized revenue.

Our take: The design-phase application supports incremental value, but customer adoption and contract renewals set the revenue timetable. We expect FY27 improvement close to the prior 10% growth thesis, with no assumption that the full long-term synergy opportunity arrives in the first year.

Model Update & Valuation Framework

Our estimates

FY26 earnings bridge: The previous revenue and expense midpoints implied $3,890M of operating profit. The new midpoints imply $3,965M, up $75M. Net interest and other expense improves by about $5M, to $490M. Applying the unchanged 18% tax rate and 193M diluted-share midpoint to that $80M pretax improvement adds about $0.34 per share. The channel accounting change adds no profit; the forecast increase therefore rests on actual operating economics.

FY27 operating bridge: We expect $10.6B revenue, 9.7% above FY26, supported by continuing AI design activity, a further IP recovery and initial joint-product sales. We assume those sales begin gradually rather than assigning an early $400M synergy contribution. A 42.5% operating margin produces $4.505B of operating profit. Less $500M net interest and other expense, taxed at 18% and divided by 193M shares, yields about $17.02 per share, rounded to our $17.00 estimate. The debt burden therefore remains in the forecast, while no aggressive share-count reduction is needed.

The prior recap did not specify a valuation multiple. We now make the method explicit: 28–34 times our FY27 EPS produces approximately $476–$578, supporting the retained rounded $480–$580 fair-value range. Our central value is 31 times $17.00, or $527. The FY27 earnings period is consistent with the outlook developed in Q1; the valuation now rests on a higher central EPS estimate within the same fair-value range.

A premium multiple is justified by essential design tools, an 83% recurring-revenue mix and the cost of replacing validated customer workflows. The range remains below what an unqualified AI-growth story might command because IP profitability has not recovered fully, China remains constrained, and joint-product adoption is still early. These are valuation assumptions, not a claim that peer multiples dictate fair value.

Twelve-month return and downside

The downside assumes IP title delivery or customer conversion disappoints, non-AI activity stays soft and reinvestment prevents the expected margin expansion. It does not require the EDA franchise to lose relevance: reported revenue still grows about 5%. The upside requires faster product adoption and savings, with better commercial conversion supporting both EPS and a higher multiple.

We assume no dividend over the next twelve months, so the scenario returns equal price returns. Our illustrative S&P 500 total-return assumption is 8% over the same horizon. The base case offers only a modest advantage over that benchmark, against materially larger execution downside. That supports Hold even after the price decline. A 100bp change in FY27 operating margin changes EPS by about $0.45 at our revenue, tax and share assumptions, illustrating why the quality of the margin progression matters as much as the next revenue beat.

Thesis Scorecard Post-Earnings

The first IP sequential improvement, named joint-product trials and initial buyback execution fulfill parts of the Q1 watch list. Broader commercial delivery, further sequential IP growth, the processor-IP closing and a quantified FY27 framework remain outstanding. The risk profile has improved; the operating conditions for an upgrade are partly met, while the return advantage remains modest.

What would change our view: Continued sequential IP improvement, commercial availability in the second half of 2026 and signed new-model IP agreements by fiscal year-end would support higher confidence. September 30 Investor Day can clarify the remaining cost savings and monetization path. We would reconsider the rating if those commitments establish earnings power above our $17 FY27 base without requiring a higher multiple; IP delays into FY27, a China deterioration or slippage against the $9.665B/41% FY26 framework would move us toward the downside case.

Overall: The thesis is stronger on operating execution and cash generation, with no resolution yet of the largest commercialization and geographic risks.

Action: Maintain Hold. We retain a $480–$580 twelve-month fair-value range and a $527 central value. Synopsys has earned higher earnings expectations; the remaining transition risk keeps the stock’s expected return close enough to the market to wait for further execution.